Enanta Pharmaceuticals Inc. (ENTA) Downgraded by Zacks Investment Research to Hold
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday.
According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
Separately, JPMorgan Chase & Co. set a $26.00 price target on Enanta Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $27.24.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/11/enanta-pharmaceuticals-inc-enta-downgraded-by-zacks-investment-research-to-hold.html
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded down 0.81% during midday trading on Tuesday, hitting $25.74. 144,615 shares of the company’s stock traded hands. The stock has a market cap of $489.96 million, a P/E ratio of 17.02 and a beta of 0.52. The company has a 50 day moving average of $24.48 and a 200 day moving average of $24.87. Enanta Pharmaceuticals has a 52 week low of $16.75 and a 52 week high of $41.77.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, August 8th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. The company earned $14 million during the quarter, compared to analysts’ expectations of $13.07 million. Enanta Pharmaceuticals had a return on equity of 11.31% and a net margin of 32.59%. The business’s revenue was up 20.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.13 EPS. On average, equities analysts forecast that Enanta Pharmaceuticals will post $1.02 EPS for the current fiscal year.
A number of large investors have recently modified their holdings of ENTA. Public Employees Retirement System of Ohio raised its stake in shares of Enanta Pharmaceuticals by 4.0% in the second quarter. Public Employees Retirement System of Ohio now owns 19,209 shares of the company’s stock valued at $424,000 after buying an additional 747 shares in the last quarter. Fiera Capital Corp bought a new stake in shares of Enanta Pharmaceuticals during the second quarter valued at $12,480,000. AQR Capital Management LLC raised its stake in shares of Enanta Pharmaceuticals by 6.5% in the second quarter. AQR Capital Management LLC now owns 46,258 shares of the company’s stock valued at $1,020,000 after buying an additional 2,822 shares in the last quarter. Guggenheim Capital LLC raised its stake in shares of Enanta Pharmaceuticals by 16.2% in the second quarter. Guggenheim Capital LLC now owns 36,718 shares of the company’s stock valued at $809,000 after buying an additional 5,118 shares in the last quarter. Finally, Senzar Asset Management LLC raised its stake in shares of Enanta Pharmaceuticals by 42.2% in the second quarter. Senzar Asset Management LLC now owns 482,000 shares of the company’s stock valued at $10,628,000 after buying an additional 143,149 shares in the last quarter. 70.82% of the stock is currently owned by hedge funds and other institutional investors.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.